On November 27, the foundation stone of Venus Medtech Life Health Industrial Park was officially laid in Binjiang District, Hangzhou. As a leading comprehensive platform company for innovative structural heart disease devices in China, Venus Medtech will build its headquarter building here to embark on the next stage.

 

Zheng Di, Acting District Mayor of Binjiang District of Hangzhou, Qiu Feizhang, former Deputy Secretary and Deputy Director-General of Science and Technology Department of Zhejiang Province, Tao Feng, Deputy District Mayor of Binjiang District, Zhan Yanqing, Director of Smart Xintiandi Development Service Center of Binjiang District, Eric Zi, Founder and General Manager of Venus Medtech, Yang Fenguo, Executive Vice Director of Bank of China (Hangzhou Branch), and representatives from other partner banks attended the cornerstone-laying ceremony.

 

Venus Medtech Life Health Industrial Park is located in Binjiang District of Hangzhou, adjacent to the Qiantang River, enjoying easy accessibility and a beautiful environment.

 

The industrial park covers an area of 43,600 square meters, with a total planned construction area of about 209,000 square meters, consisting of four main buildings and three podium buildings. It is designed as a multi-functional life health industrial park integrating office headquarters, GMP factory, laboratory and research institute, adding a new landmark combining humanity, intelligence and ecology to the bank of the Qiantang River.

Tao Feng, Deputy District Mayor of Binjiang District, noted in his speech that Venus Medtech was an outstanding company incubated in Binjiang District, rising to a model and benchmark for the Chinese heart valve industry in just a decade. This industrial park will make another milestone in the company’s history. He sincerely hoped that Venus Medtech would take this opportunity to promote industrial innovation and high-quality development, continuously improve its core competitiveness, make even greater contributions to China’s medical device sector, and create a better future together with the High-tech Zone (Binjiang).”

 

Yang Fenguo, Executive Vice Director of Bank of China Hangzhou Branch, said it was a great honor to witness the groundbreaking of Venus Medtech Life Health Industrial Park. "We will leverage our globalized and integrated operation to actively promote the convergence of healthcare and technology and empower R&D of innovative medical technology with financial services. Under the leadership of Binjiang District CPC Committee and Government, we look forward to joining hands with Venus Medtech to create a better future. We will jointly build a new ecosystem for the development of medical technology in Zhejiang province, thus making our best contribution to the economic and social development of Binjiang District."

 

Eric Zi, Founder and General Manager of Venus Medtech, said that the successful foundation laying of Venus Medtech Life Health Industrial Park was inseparable from the support of authorities at all levels in Binjiang. This is not only a milestone but also a new beginning for everybody at the company. The Qiantang River will continue to be a productive cradle of groundbreaking medical technologies unprecedented in the country to benefit more patients and bring more innovative medical technologies to the historic city of Hangzhou."

 

Venus Medtech (2500.HK) is China’s leading player in transcatheter structural heart valvular therapies. Founded in 2009 in Hangzhou, the Company enjoys first mover advantages with a strong track record of innovative R&D. VenusA-Valve and VenusA-Plus, self-developed first-gen and second-gen TAVR products, are the world's first products approved by the National Medical Products Administration (NMPA) and commercialized in China. In terms of R&D layout, the company has built a number of technical platforms in order to move into the fields of hypertrophic cardiomyopathy, hypertension interventional therapy, and even heart failure treatment, besides heart valve disease, and is committed to providing a complete integrated solution for structural heart disease.